These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 12430588)

  • 1. Markers and residual time to AIDS.
    Geskus RB
    Neth J Med; 2002 Aug; 60(7 Suppl):27-32; discussion 32-4. PubMed ID: 12430588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein is a marker for human immunodeficiency virus disease progression.
    Lau B; Sharrett AR; Kingsley LA; Post W; Palella FJ; Visscher B; Gange SJ
    Arch Intern Med; 2006 Jan; 166(1):64-70. PubMed ID: 16401812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A flexible B-spline model for multiple longitudinal biomarkers and survival.
    Brown ER; Ibrahim JG; DeGruttola V
    Biometrics; 2005 Mar; 61(1):64-73. PubMed ID: 15737079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response.
    Moore DM; Hogg RS; Chan K; Tyndall M; Yip B; Montaner JS
    AIDS; 2006 Feb; 20(3):371-7. PubMed ID: 16439870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
    Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
    Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection.
    Sevigny JJ; Albert SM; McDermott MP; Schifitto G; McArthur JC; Sacktor N; Conant K; Selnes OA; Stern Y; McClernon DR; Palumbo D; Kieburtz K; Riggs G; Cohen B; Marder K; Epstein LG
    Arch Neurol; 2007 Jan; 64(1):97-102. PubMed ID: 17210815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
    AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection.
    Kiwanuka N; Laeyendecker O; Robb M; Kigozi G; Arroyo M; McCutchan F; Eller LA; Eller M; Makumbi F; Birx D; Wabwire-Mangen F; Serwadda D; Sewankambo NK; Quinn TC; Wawer M; Gray R
    J Infect Dis; 2008 Mar; 197(5):707-13. PubMed ID: 18266607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating surrogate markers of clinical outcome when measured with error.
    Dafni UG; Tsiatis AA
    Biometrics; 1998 Dec; 54(4):1445-62. PubMed ID: 9883544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.
    Tarwater PM; Gallant JE; Mellors JW; Gore ME; Phair JP; Detels R; Margolick JB; Muñoz A
    AIDS; 2004 Dec; 18(18):2419-23. PubMed ID: 15622318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients.
    Goujard C; Bonarek M; Meyer L; Bonnet F; Chaix ML; Deveau C; Sinet M; Galimand J; Delfraissy JF; Venet A; Rouzioux C; Morlat P;
    Clin Infect Dis; 2006 Mar; 42(5):709-15. PubMed ID: 16447119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling the relationship between continuous covariates and clinical events using isotonic regression.
    Ancukiewicz M; Finkelstein DM; Schoenfeld DA
    Stat Med; 2003 Oct; 22(20):3151-9. PubMed ID: 14518020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
    Mildvan D; Spritzler J; Grossberg SE; Fahey JL; Johnston DM; Schock BR; Kagan J
    Clin Infect Dis; 2005 Mar; 40(6):853-8. PubMed ID: 15736019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of treatment interruption duration in a cohort of HIV-1 infected patients with CD4 count greater than 350 cells per mm3.
    Fillaux J; Delpierre C; Alvarez M; Jaafar A; Marchou B; Massip P; Cuzin L
    Med Mal Infect; 2006 Jun; 36(6):335-9. PubMed ID: 16631330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians.
    Mekonnen Y; Dukers NH; Sanders E; Dorigo W; Wolday D; Schaap A; Geskus RB; Coutinho RA; Fontanet A
    Ethiop Med J; 2003 Jun; 41 Suppl 1():61-5. PubMed ID: 15227882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.